系统综述:甲氨蝶呤——在炎症性肠病中被认识不足且使用不足的药物
本文系统综述了甲氨蝶呤治疗成人炎症性肠病的疗效、安全性、最佳剂量与给药方案。对克罗恩病,8项随机对照试验和17项观察性研究显示,肠外甲氨蝶呤25 mg/周用16周可有效提高激素依赖患者的缓解率,15 mg/周用于维持;与抗肿瘤坏死因子(TNF)药物联用可减少免疫原性。对溃疡性结肠炎,5项随机对照试验和10项观察性研究无证据支持甲氨蝶呤的使用。安全性数据来自17项研究,轻中度不良反应常见,肝纤维化或肝硬化发生率低。结论认为甲氨蝶呤对激素难治性克罗恩病诱导和维持缓解有效,联用时可减少抗TNF诱导的免疫原性,耐受性和安全性数据令人放心,这些发现挑战了对甲氨蝶呤的成见,并提示其是治疗轻中度克罗恩病的有效一线传统选择。
要点
- 肠外甲氨蝶呤25 mg/周用16周可有效提高激素依赖克罗恩病患者的缓解率,15 mg/周用于维持。
- 甲氨蝶呤与抗TNF药物联用可减少免疫原性。
- 无证据支持甲氨蝶呤用于溃疡性结肠炎。
核心结论
- 甲氨蝶呤对激素难治性克罗恩病诱导和维持缓解有效,与抗TNF药物联用时可减少抗TNF诱导的免疫原性。
- 甲氨蝶呤的耐受性和安全性数据令人放心。
- 这些发现挑战了对甲氨蝶呤的成见,并提示其是治疗轻中度克罗恩病的有效一线传统选择。
研究设计与样本
- 系统综述,检索MEDLINE(通过PubMed)自建库至2023年8月,纳入接受甲氨蝶呤治疗的炎症性肠病患者研究。
- 克罗恩病纳入8项随机对照试验和17项观察性研究。
- 溃疡性结肠炎纳入5项随机对照试验和10项观察性研究。
- 安全性数据从17项研究中提取。
主要发现
- 克罗恩病:肠外甲氨蝶呤25 mg/周用16周有效提高激素依赖患者的缓解率,15 mg/周用于维持。
- 甲氨蝶呤可与抗TNF药物联用以减少免疫原性。
- 比较硫嘌呤与甲氨蝶呤的数据仍 scarce。
- 溃疡性结肠炎:无证据支持甲氨蝶呤的使用。
- 安全性:轻中度不良反应常见,肝纤维化或肝硬化发生率低。
局限性
- 比较硫嘌呤与甲氨蝶呤的数据仍 scarce。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Methotrexate, an immunosuppressant used for the treatment of inflammatory bowel disease (IBD) for over 30 years, remains underused compared to thiopurines. AIMS: To review the efficacy, safety, optimal dosing and delivery regimens of methotrexate in adults with IBD. METHODS: We conducted a systematic review of studies involving patients with IBD treated with methotrexate from inception to August 2023. All studies were included from the MEDLINE database via PubMed. RESULTS: For Crohn's disease, we included eight randomised controlled trials (RCTs) and 17 observational studies. Parenteral methotrexate effectively increased remission rates in steroid-dependent patients at 25 mg/week for 16 weeks and at 15 mg/week for maintenance. Methotrexate can be used in combination with anti-tumour necrosis factor (TNF) agents to reduce immunogenicity. Data comparing thiopurines and methotrexate remain scarce. For ulcerative colitis (UC), we included five RCTs and 10 observational studies were included; there was no evidence to support the use of methotrexate in (UC). We extracted safety data from 17 studies; mild-to-moderate adverse effects were common. The incidence of liver fibrosis or cirrhosis was low. CONCLUSION: Methotrexate is effective at inducing and maintaining remission in steroid-refractory Crohn's disease and can reduce anti-TNF-induced immunogenicity when used in combination therapy. Data regarding tolerance and safety are reassuring. These findings challenge preconceived ideas on methotrexate and suggest that it is a valid first-line conventional option for the treatment of mild-to-moderate Crohn's disease.
引用
- Sequier L, Caron B, Loeuille D, et al. Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease. Aliment Pharmacol Ther. 2024. PMID: 39076140. doi:10.1111/apt.18194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。